Venovenous ECMO for severe COVID-19 led to ‘exceptional early survival’ that was sustained

Patients with severe COVID-19 who received venovenous extracorporeal membrane oxygenation support had “exceptional early survival” to discharge that was sustained 1 year after cannulation, researchers reported in Annals of Thoracic Surgery.
“[With] appropriately selected patients and aggressive management strategies, the use of ECMO support in patients with severe COVID-19 can result in exceptional early survival that, in this cohort, was sustained 1 year after ECMO cannulation,” Deane E. Smith, MD, cardiac surgeon in the department of cardiothoracic surgery, director

Patients with severe COVID-19 who received venovenous extracorporeal membrane oxygenation support had “exceptional early survival” to discharge that was sustained 1 year after cannulation, researchers reported in Annals of Thoracic Surgery.
“[With] appropriately selected patients and aggressive management strategies, the use of ECMO support in patients with severe COVID-19 can result in exceptional early survival that, in this cohort, was sustained 1 year after ECMO cannulation,” Deane E. Smith, MD, cardiac surgeon in the department of cardiothoracic surgery, director